Subscribe to:
Post Comments (Atom)
skip to main |
skip to sidebar
Viral Matters focuses on all aspects of Direct Acting Antivirals (DAA) and Antiretrovirals in development and on the market.
Pages
Search This Blog
About Me
- Chris Barnes
- Redondo Beach, CA, United States
- A 17 year veteran of Medical Affairs and Commercial functions of the biopharma and pharmaceutical industry, with expertise in Hepatitis and HIV. christopherjbarnes10@gmail.com
Posts
Followers
Blog Archive
-
▼
2011
(194)
-
▼
July
(16)
- Vertex's Telaprevir beats Wall Street expectations...
- Interim Data from Phase 2 Study of Combination Reg...
- NanoViricides announces anti-HIV therapy could lea...
- Genotype 1b HCV Patients Fare Better on Boceprevir
- Sexual transmission of HCV virus more prevalent th...
- Merck and Roche sign global agreement to promote V...
- InPharm article on Telaprevir vs Boceprevir in the...
- The EU approves Boceprevir for treatment of chroni...
- Gilead first company to share AIDS and HBV drugs w...
- Achillion Pharmaceuticals launches Phase 1 study o...
- The Motley Fool on the J&J/Pharmasset partnership....
- Noninvasive tests predicted survival in chronic he...
- Medivir/Tibotec's HCV protease inhibitor TMC435 re...
- Join "Viral Matters" HCV drug development discussi...
- Pharmasset & Tibotec team up HCV drugs in clinical...
- Pharmasset's PSI-7977 deemed having "Blockbuster p...
-
▼
July
(16)
No comments:
Post a Comment